Bedrijfsoverzicht
Oramed Pharmaceuticals Inc. is a biotechnology entity focused on the research and development of pharmaceutical solutions, specifically utilizing a proprietary technology platform designed for the oral delivery of therapeutic proteins. The company operates within the broader healthcare sector, with its specific industry classification being biotechnology, which implies a high-risk, high-reward environment driven by innovation and rigorous clinical validation. As of the latest data, the company possesses a market capitalization of $142.78M and reports annual revenue of $2.00M, though the specific employee count is not disclosed in available records. These valuation and revenue figures indicate that Oramed operates as a small-cap entity with significant cash reserves relative to its current sales volume, suggesting a firm still in a growth or clinical development phase rather than a mature, cash-flow-positive operation.
Financiële gezondheid
The financial statements for the trailing twelve months reveal a revenue of $2.00M alongside a reported net income of $63.24M and an EBITDA of -$14,967,000. The substantial gap between the modest revenue figure and the reported net income indicates a severe distortion in the standard cost structure calculation, likely resulting from significant non-operating gains or specific accounting treatments that inflate the bottom line despite negative operating cash flows. Despite the negative EBITDA, the company maintains a free cash flow of $3.92M, which provides essential financial flexibility to fund ongoing research and development activities without immediate reliance on external equity financing. The gross margin stands at 0.6%, while the operating margin is a negative 754.4%, and the profit margin is reported at 3202.5%; these divergent figures highlight that the company is not yet profitable from operations but is generating returns on equity of 37.1% through financial engineering or asset valuation adjustments. In terms of solvency, the company holds $125.89M in cash against only $825,000 in debt, supported by a debt-to-equity ratio of 0.41, which suggests a highly conservative balance sheet with minimal leverage risk. Liquidity is robust, evidenced by a current ratio of 6.98, indicating that the company possesses nearly seven times the current assets necessary to cover its short-term obligations. Furthermore, the return on assets is -4.9%, which contrasts sharply with the high return on equity, revealing that while management is effective at leveraging equity to generate nominal income, the underlying asset base is not yet contributing positively to operational profitability.
Waarderingsbeoordeling
The valuation metrics present a complex picture, with a trailing P/E ratio of 2.35 and a forward P/E of -44.12. The stark difference between these two figures implies that while the company currently reports earnings due to non-operating factors, analysts do not expect these earnings to persist into the future, leading to a negative forward valuation multiple. The price-to-book ratio is 0.71, indicating that the market values the company at a discount to its book value, which is common for biotechnology firms where intangible assets and clinical trial risks are not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 71.39 and an EV/EBITDA of -1.18 suggest that the market is pricing the company based on its clinical pipeline potential rather than current financial performance. Regarding trading range, the stock has seen a 52-week high of $3.76 and a 52-week low of $1.98, meaning the current price sits within this historical volatility band but is significantly below the recent peak. The beta value of 1.25 indicates that the stock's price volatility is 25% higher than the broader market, reflecting the inherent risks associated with small-cap biotechnology investments and the specific uncertainties surrounding the company's Phase III clinical trials for ORMD-0801.
Growth & Income
The available data indicates that revenue growth year-over-year and earnings growth year-over-year are listed as N/A, preventing a direct comparison of growth rates between earnings and revenue. Consequently, it is impossible to determine from the provided facts whether earnings are growing faster or slower than revenue, as the historical growth trajectory data is not disclosed. Regarding income generation, the company offers a dividend yield of 7.1% with a payout ratio of 0.0%. This unique combination suggests that while the company distributes a high percentage of its market value or assets as a dividend yield, the payout ratio of zero implies that the dividend is not funded by current earnings or cash flow, but rather by the substantial cash balance or capitalization of the company. This structure is typical for biotechnology firms that prioritize capital allocation to research and development over traditional dividend sustainability models. The overall growth and income profile for Oramed Pharmaceuticals is characterized by a lack of historical growth data, a reliance on cash reserves for operations, and a high-yield dividend that does not reflect current earnings generation, creating a speculative investment profile driven entirely by the potential success of future pharmaceutical products.